Combination Therapy for Myelomatosis
Twenty-eight patients with multiple myeloma have been treated with a quadruple chemotherapeutic regimen consisting of 1, 3 bis (2-chloroethyl)-1-nitrosourea (BCNU), cyclophosphamide, melphalan, and prednisolone. Nineteen new patients and nine who had escaped from previous single-agent therapy were i...
Gespeichert in:
| Veröffentlicht in: | BMJ 1974-12, Vol.4 (5944), p.560-564 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 564 |
|---|---|
| container_issue | 5944 |
| container_start_page | 560 |
| container_title | BMJ |
| container_volume | 4 |
| creator | Azam, L. Delamore, I. W. |
| description | Twenty-eight patients with multiple myeloma have been treated with a quadruple chemotherapeutic regimen consisting of 1, 3 bis (2-chloroethyl)-1-nitrosourea (BCNU), cyclophosphamide, melphalan, and prednisolone. Nineteen new patients and nine who had escaped from previous single-agent therapy were included in the study. The results to date, on eight criteria of response, seem to be superior to those obtained from previous chemotherapeutic regimens. The study has been in progress for 18 months and only three patients have died. Only one who had not received previous therapy died, and she had complicating hyperparathyroidism, which almost certainly contributed to her death. |
| doi_str_mv | 10.1136/bmj.4.5944.560 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1612723</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>20471299</jstor_id><sourcerecordid>20471299</sourcerecordid><originalsourceid>FETCH-LOGICAL-b507t-93924ef929e59518d189d9ffcd504a44d46d42e4dc6a8643514f1bcd86edb8663</originalsourceid><addsrcrecordid>eNqFkEtPGzEURi1URCNgy65SpHbDYoIf169NpSpQiqAgoZBK3ViesadMyIyDPUHNv6-jRAFW3diyzvG9nz6ETggeEcLEWdnORjDiGvIh8B4aEBCq4IqxD2iAMZYFAZAf0XFKs_ykTCot4AAdgCCEKz5AX8ahLZvO9k3ohpNHH-1iNaxDHP5c-XlobR9Sk47Qfm3nyR9v70P08P1iMv5R3NxdXo2_3RQlx7IvNNMUfK2p9lxzohxR2um6rhzHYAEcCAfUg6uEVQIYJ1CTsnJKeFcqIdgh-rqZu1iWrXeV7_po52YRm9bGlQm2Me9J1zyaP-HFEEGopCwP-LwdEMPz0qfezMIydjmzIVJmiTKxtkYbq4ohpejr3QaCzbpXk3s1YNa9mtxr_vDpba6dvm3xlc9SH-IOUwySUK0zLza8Sb3_u-M2PhkhmeTmdjo2v_n9-fXlLzDT7J9u_HWO_2T7ByudmLE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776122363</pqid></control><display><type>article</type><title>Combination Therapy for Myelomatosis</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>PubMed Central</source><creator>Azam, L. ; Delamore, I. W.</creator><creatorcontrib>Azam, L. ; Delamore, I. W.</creatorcontrib><description>Twenty-eight patients with multiple myeloma have been treated with a quadruple chemotherapeutic regimen consisting of 1, 3 bis (2-chloroethyl)-1-nitrosourea (BCNU), cyclophosphamide, melphalan, and prednisolone. Nineteen new patients and nine who had escaped from previous single-agent therapy were included in the study. The results to date, on eight criteria of response, seem to be superior to those obtained from previous chemotherapeutic regimens. The study has been in progress for 18 months and only three patients have died. Only one who had not received previous therapy died, and she had complicating hyperparathyroidism, which almost certainly contributed to her death.</description><identifier>ISSN: 0007-1447</identifier><identifier>ISSN: 0959-8138</identifier><identifier>EISSN: 1468-5833</identifier><identifier>DOI: 10.1136/bmj.4.5944.560</identifier><identifier>PMID: 4611585</identifier><language>eng</language><publisher>England: British Medical Journal Publishing Group</publisher><subject>Blood ; Bone marrow cells ; Bone Marrow Examination ; Calcium ; Calcium - blood ; Carmustine - administration & dosage ; Carmustine - therapeutic use ; Chemotherapy ; Clinical Trials as Topic ; Cyclophosphamide - administration & dosage ; Cyclophosphamide - therapeutic use ; Dosage ; Drug Therapy, Combination ; Globulins ; Hemoglobins ; Hemoglobins - analysis ; Humans ; Immunoglobulin Fragments - urine ; Immunoglobulins - analysis ; Kidney Function Tests ; Melphalan - administration & dosage ; Melphalan - therapeutic use ; Multiple Myeloma - blood ; Multiple Myeloma - drug therapy ; Multiple Myeloma - mortality ; Myeloma Proteins - analysis ; Papers and Originals ; Paraproteins ; Plasmacytoma - drug therapy ; Prednisolone - administration & dosage ; Prednisolone - therapeutic use ; Renal clearance ; Response rates ; Serum Albumin - analysis</subject><ispartof>BMJ, 1974-12, Vol.4 (5944), p.560-564</ispartof><rights>Copyright 1974 British Medical Journal</rights><rights>Copyright BMJ Publishing Group LTD Dec 7, 1974</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b507t-93924ef929e59518d189d9ffcd504a44d46d42e4dc6a8643514f1bcd86edb8663</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/20471299$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/20471299$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,725,778,782,801,883,27907,27908,53774,53776,58000,58233</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/4611585$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Azam, L.</creatorcontrib><creatorcontrib>Delamore, I. W.</creatorcontrib><title>Combination Therapy for Myelomatosis</title><title>BMJ</title><addtitle>Br Med J</addtitle><description>Twenty-eight patients with multiple myeloma have been treated with a quadruple chemotherapeutic regimen consisting of 1, 3 bis (2-chloroethyl)-1-nitrosourea (BCNU), cyclophosphamide, melphalan, and prednisolone. Nineteen new patients and nine who had escaped from previous single-agent therapy were included in the study. The results to date, on eight criteria of response, seem to be superior to those obtained from previous chemotherapeutic regimens. The study has been in progress for 18 months and only three patients have died. Only one who had not received previous therapy died, and she had complicating hyperparathyroidism, which almost certainly contributed to her death.</description><subject>Blood</subject><subject>Bone marrow cells</subject><subject>Bone Marrow Examination</subject><subject>Calcium</subject><subject>Calcium - blood</subject><subject>Carmustine - administration & dosage</subject><subject>Carmustine - therapeutic use</subject><subject>Chemotherapy</subject><subject>Clinical Trials as Topic</subject><subject>Cyclophosphamide - administration & dosage</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Dosage</subject><subject>Drug Therapy, Combination</subject><subject>Globulins</subject><subject>Hemoglobins</subject><subject>Hemoglobins - analysis</subject><subject>Humans</subject><subject>Immunoglobulin Fragments - urine</subject><subject>Immunoglobulins - analysis</subject><subject>Kidney Function Tests</subject><subject>Melphalan - administration & dosage</subject><subject>Melphalan - therapeutic use</subject><subject>Multiple Myeloma - blood</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - mortality</subject><subject>Myeloma Proteins - analysis</subject><subject>Papers and Originals</subject><subject>Paraproteins</subject><subject>Plasmacytoma - drug therapy</subject><subject>Prednisolone - administration & dosage</subject><subject>Prednisolone - therapeutic use</subject><subject>Renal clearance</subject><subject>Response rates</subject><subject>Serum Albumin - analysis</subject><issn>0007-1447</issn><issn>0959-8138</issn><issn>1468-5833</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1974</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkEtPGzEURi1URCNgy65SpHbDYoIf169NpSpQiqAgoZBK3ViesadMyIyDPUHNv6-jRAFW3diyzvG9nz6ETggeEcLEWdnORjDiGvIh8B4aEBCq4IqxD2iAMZYFAZAf0XFKs_ykTCot4AAdgCCEKz5AX8ahLZvO9k3ohpNHH-1iNaxDHP5c-XlobR9Sk47Qfm3nyR9v70P08P1iMv5R3NxdXo2_3RQlx7IvNNMUfK2p9lxzohxR2um6rhzHYAEcCAfUg6uEVQIYJ1CTsnJKeFcqIdgh-rqZu1iWrXeV7_po52YRm9bGlQm2Me9J1zyaP-HFEEGopCwP-LwdEMPz0qfezMIydjmzIVJmiTKxtkYbq4ohpejr3QaCzbpXk3s1YNa9mtxr_vDpba6dvm3xlc9SH-IOUwySUK0zLza8Sb3_u-M2PhkhmeTmdjo2v_n9-fXlLzDT7J9u_HWO_2T7ByudmLE</recordid><startdate>19741207</startdate><enddate>19741207</enddate><creator>Azam, L.</creator><creator>Delamore, I. W.</creator><general>British Medical Journal Publishing Group</general><general>British Medical Association</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>19741207</creationdate><title>Combination Therapy for Myelomatosis</title><author>Azam, L. ; Delamore, I. W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b507t-93924ef929e59518d189d9ffcd504a44d46d42e4dc6a8643514f1bcd86edb8663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1974</creationdate><topic>Blood</topic><topic>Bone marrow cells</topic><topic>Bone Marrow Examination</topic><topic>Calcium</topic><topic>Calcium - blood</topic><topic>Carmustine - administration & dosage</topic><topic>Carmustine - therapeutic use</topic><topic>Chemotherapy</topic><topic>Clinical Trials as Topic</topic><topic>Cyclophosphamide - administration & dosage</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Dosage</topic><topic>Drug Therapy, Combination</topic><topic>Globulins</topic><topic>Hemoglobins</topic><topic>Hemoglobins - analysis</topic><topic>Humans</topic><topic>Immunoglobulin Fragments - urine</topic><topic>Immunoglobulins - analysis</topic><topic>Kidney Function Tests</topic><topic>Melphalan - administration & dosage</topic><topic>Melphalan - therapeutic use</topic><topic>Multiple Myeloma - blood</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - mortality</topic><topic>Myeloma Proteins - analysis</topic><topic>Papers and Originals</topic><topic>Paraproteins</topic><topic>Plasmacytoma - drug therapy</topic><topic>Prednisolone - administration & dosage</topic><topic>Prednisolone - therapeutic use</topic><topic>Renal clearance</topic><topic>Response rates</topic><topic>Serum Albumin - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Azam, L.</creatorcontrib><creatorcontrib>Delamore, I. W.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMJ</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Azam, L.</au><au>Delamore, I. W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination Therapy for Myelomatosis</atitle><jtitle>BMJ</jtitle><addtitle>Br Med J</addtitle><date>1974-12-07</date><risdate>1974</risdate><volume>4</volume><issue>5944</issue><spage>560</spage><epage>564</epage><pages>560-564</pages><issn>0007-1447</issn><issn>0959-8138</issn><eissn>1468-5833</eissn><abstract>Twenty-eight patients with multiple myeloma have been treated with a quadruple chemotherapeutic regimen consisting of 1, 3 bis (2-chloroethyl)-1-nitrosourea (BCNU), cyclophosphamide, melphalan, and prednisolone. Nineteen new patients and nine who had escaped from previous single-agent therapy were included in the study. The results to date, on eight criteria of response, seem to be superior to those obtained from previous chemotherapeutic regimens. The study has been in progress for 18 months and only three patients have died. Only one who had not received previous therapy died, and she had complicating hyperparathyroidism, which almost certainly contributed to her death.</abstract><cop>England</cop><pub>British Medical Journal Publishing Group</pub><pmid>4611585</pmid><doi>10.1136/bmj.4.5944.560</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1447 |
| ispartof | BMJ, 1974-12, Vol.4 (5944), p.560-564 |
| issn | 0007-1447 0959-8138 1468-5833 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1612723 |
| source | MEDLINE; Jstor Complete Legacy; PubMed Central |
| subjects | Blood Bone marrow cells Bone Marrow Examination Calcium Calcium - blood Carmustine - administration & dosage Carmustine - therapeutic use Chemotherapy Clinical Trials as Topic Cyclophosphamide - administration & dosage Cyclophosphamide - therapeutic use Dosage Drug Therapy, Combination Globulins Hemoglobins Hemoglobins - analysis Humans Immunoglobulin Fragments - urine Immunoglobulins - analysis Kidney Function Tests Melphalan - administration & dosage Melphalan - therapeutic use Multiple Myeloma - blood Multiple Myeloma - drug therapy Multiple Myeloma - mortality Myeloma Proteins - analysis Papers and Originals Paraproteins Plasmacytoma - drug therapy Prednisolone - administration & dosage Prednisolone - therapeutic use Renal clearance Response rates Serum Albumin - analysis |
| title | Combination Therapy for Myelomatosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T16%3A00%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20Therapy%20for%20Myelomatosis&rft.jtitle=BMJ&rft.au=Azam,%20L.&rft.date=1974-12-07&rft.volume=4&rft.issue=5944&rft.spage=560&rft.epage=564&rft.pages=560-564&rft.issn=0007-1447&rft.eissn=1468-5833&rft_id=info:doi/10.1136/bmj.4.5944.560&rft_dat=%3Cjstor_pubme%3E20471299%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1776122363&rft_id=info:pmid/4611585&rft_jstor_id=20471299&rfr_iscdi=true |